Background The efficacy of interleukin-6 receptor antagonists in critically ill patients with
coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and …

Purpose To study the efficacy of lopinavir-ritonavir and hydroxychloroquine in critically ill
patients with coronavirus disease 2019 (COVID-19). Methods Critically ill adults with COVID-19 …

BACKGROUND The interleukin-6 receptor antagonist tocilizumab improves outcomes in
critically ill patients with coronavirus disease 2019 (COVID-19). However, the effectiveness of …

Importance Randomized clinical trials (RCTs) of therapeutic-dose heparin in patients hospitalized
with COVID-19 produced conflicting results, possibly due to heterogeneity of treatment …

Importance The effectiveness of monoclonal antibodies (mAbs), casirivimab-imdevimab and
sotrovimab, is unknown in patients with mild to moderate COVID-19 caused by the SARS-…

Interventions Patients were randomized to receive either open-label aspirin (n= 565), a
P2Y12 inhibitor (n= 455), or no antiplatelet therapy (control; n= 529). Interventions were …

Importance Monoclonal antibody (mAb) treatment decreases hospitalization and death in
high-risk outpatients with mild to moderate COVID-19; however, only intravenous …

We develop and exemplify application of new classes of dynamic models for time series of
nonnegative counts. Our novel univariate models combine dynamic generalized linear …

We present new Bayesian methodology for consumer sales forecasting. Focusing on the
multi-step-ahead forecasting of daily sales of many supermarket items, we adapt dynamic count …

Background A recent prospective meta-analysis demonstrated that interleukin-6 antagonists
are associated with lower all-cause mortality in hospitalised patients with COVID-19, …